share_log

德琪醫藥-B：截至2024年3月31日止月份之股份發行人的證券變動月報表

ANTENGENE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

香港交易所 ·  Apr 3 04:53
Summary by Moomoo AI
德琪醫藥有限公司於2024年4月3日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的公司股份變動情況。報告顯示，公司的法定/註冊股本結存維持在2,000,000,000股，每股面值0.0001美元，總額200,000美元，本月內無增減變動。此外，公司的股份期權計劃中，2019股權激勵計劃及2020股權激勵計劃分別註銷了33,120股和12,000股股份期權，但本月內無新股份因行使期權而發行。報告亦指出，其他發行將予上市的發行股份的協議或安排（包括期權）本月內無新股份發行。整體來看，德琪醫藥本月的已發行股份數量保持不變。
德琪醫藥有限公司於2024年4月3日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的公司股份變動情況。報告顯示，公司的法定/註冊股本結存維持在2,000,000,000股，每股面值0.0001美元，總額200,000美元，本月內無增減變動。此外，公司的股份期權計劃中，2019股權激勵計劃及2020股權激勵計劃分別註銷了33,120股和12,000股股份期權，但本月內無新股份因行使期權而發行。報告亦指出，其他發行將予上市的發行股份的協議或安排（包括期權）本月內無新股份發行。整體來看，德琪醫藥本月的已發行股份數量保持不變。
DEKI PHARMACEUTICALS LIMITED FILED ITS LATEST MONTHLY SECURITIES CHANGE REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON APRIL 3, 2024, REPORTING CHANGES IN COMPANY SHARES AS OF MARCH 31, 2024. The report showed that the company's regulated/registered capital deposit remained at 2,000,000,000 shares with a face value of $0.0001 per share for a total of $200,000, with no increase or decrease in the month. In addition, 33,120 shares and 12,000 share options were written off in the Company's Stock Option Plan 2019 and Stock Incentive Program 2020, respectively, but no new shares were issued this month as a result of the exercise of the options. The report also noted that no new share issuance agreements or arrangements (including options) for other issuable shares to be issued to the public will be issued during this month. Overall, the number of issued shares in Deci Pharmaceuticals remained unchanged this month.
DEKI PHARMACEUTICALS LIMITED FILED ITS LATEST MONTHLY SECURITIES CHANGE REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON APRIL 3, 2024, REPORTING CHANGES IN COMPANY SHARES AS OF MARCH 31, 2024. The report showed that the company's regulated/registered capital deposit remained at 2,000,000,000 shares with a face value of $0.0001 per share for a total of $200,000, with no increase or decrease in the month. In addition, 33,120 shares and 12,000 share options were written off in the Company's Stock Option Plan 2019 and Stock Incentive Program 2020, respectively, but no new shares were issued this month as a result of the exercise of the options. The report also noted that no new share issuance agreements or arrangements (including options) for other issuable shares to be issued to the public will be issued during this month. Overall, the number of issued shares in Deci Pharmaceuticals remained unchanged this month.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more